• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
By KEVIN CURRAN Jan 03, 2019 | 11:54 AM EST
Stocks quotes in this article: CELG, BMY, AMGN, MRK

Celgene Corp. (CELG) is soaring on Thursday as the announcement of a $74 billion acquisition deal brought to the table by Bristol-Myers Squibb (BMY) hits the presses.

Shares of the Summit, N.J.-based pharmaceutical company soared 25% higher on Thursday morning as Bristol-Myers offers about a 54% premium on Wednesday's closing value, valuing Celgene shares at $102.43 each, according to the announcement. By contrast, Bristol-Myers stock is barreling downward, losing some 12% in morning trading.

"Bristol-Myers Squibb's offer to buy Celgene for $74 billion is a best case scenario that should be immediately utilized by Celgene shareholders, who we would recommend take advantage of the recent deal announcement upside before the deal closes," Leerink Partners analyst Geoffrey C. Porges said on Thursday morning. 

The deal is slated to be accretive to Bristol-Myers on the basis of Celgene's pipeline of cancer treatments and cardiovascular medicines.

"As a combined entity, we will enhance our leadership positions across our portfolio, including in cancer and immunology and inflammation," Bristol-Myers CEO Giovanni Caforio said. "Together, our pipeline holds significant promise for patients, allowing us to accelerate new options through a broader range of cutting-edge technologies and discovery platforms."

The company expects to realize $2.5 billion in annual synergies by 2022 from the deal.

To be sure, the opportunity hangs on a knife's edge as the reaction of Bristol-Myers' sliding share price will be pivotal to the profitability of the deal, which is a cause for caution.

"If Bristol's stock remains at a price of ~$44, then the premium falls to 41% and 55%, respectively," Porges explained. "Given this potential premium erosion, and the risk that Bristol shareholders may reject this deal if the BMY price drop sticks, we would recommend the current CELG upside of ~30% as an exit opportunity for CELG shareholders."

Additionally, the patent cliff that confronts Celgene's cancer drug cash-cow Revlimid hangs over the deal.

Wells Fargo analyst Jim Birchenough cited the drug as a "fundamental risk" to the deal closing and Celgene maintaining its newfound heights.

"Risks include failure to prevail in ongoing REVLIMID patent litigation, failure of diversification strategy beyond REVLIMID to emerge, or clinical trial failure for REVLIMID or later stage pipeline assets," he explained.

That is not to mention the significant challenge that Merck's (MRK) Keytruda offering presents to the flagship product.

Eliquis, a major cardiovascular offering from Celgene, also faces patent problems, adding uncertainty to the deal's close.

M&A Forecast

For those not willing to jump in and trade on the agreement with so many questions still hanging in the air, analysts were happy to look ahead to what this means for biotech buyouts in 2019.

"Is biotech consolidation on the way? We are very curious to see if this marks the beginning," Cantor Fitzgerald analyst Alethia Young wrote on Thursday. "We also wonder what this means for other large pharma including Amgen (AMGN) and their appetite to do larger deals."

The move could provoke a change in strategy among large biotech companies, as major companies may need to consolidate to compete with larger entities that mega-mergers these types of deals will create.

"We view this deal as a significant shift from current Biopharma strategy, but we can appreciate the rationale with large cap biotechs having been more single product/asset stories that are starting to mature in growth," Young added. "They make attractive targets for companies looking for financial engineering deals over time as well."

Prospecting new targets will be a primary push for pharma investors in 2019 and will remain a focus for Real Money as a result.

For more on the details of the deal, check out Real Money's sister site The Deal.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

Action Alerts PLUS, which Cramer manages as a charitable trust, is long AMGN.

TAGS: Mergers and Acquisitions | Rumor Mill | Investing | Markets | Stocks | Biotechnology | Pharmaceuticals | Analyst Actions

More from Stocks

This Market Calls for Short-Term Plans

James "Rev Shark" DePorre
Aug 9, 2022 4:44 PM EDT

Looming price data and expected volatility could offer opportunities for very short-term traders, but building longer-term positions is a tougher task.

These 3 ETFs Offer Yield-Hungry Investors Some 'Options'

Mark Abssy
Aug 9, 2022 2:00 PM EDT

As our appetite expands to 'take what we can get' investments, let's look at three funds from Global X and see how they stack up against major index funds.

The World Gets Worse as Inflation Gets Better?

Peter Tchir
Aug 9, 2022 12:50 PM EDT

Here's the shift in the narrative I expect over the coming days.

The Bullish vs. Bearish Narrative on the Market

James "Rev Shark" DePorre
Aug 9, 2022 11:23 AM EDT

The CPI report Wednesday is going to cause a more careful examination of inflation, a hawkish Fed, and a potential recession.

I Don't Have Much of an Appetite for Red Robin Ahead of Earnings

Bruce Kamich
Aug 9, 2022 10:45 AM EDT

The restaurant chain reports quarterly numbers Wednesday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • 08:54 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The Secret to Dealing With FOMO
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login